COPENHAGEN (MedPage Today) -- The amyloid plaque-busting drug crenezumab for Alzheimer's disease slowed cognitive decline in patients with mild baseline impairment but missed its primary endpoint in a phase II trial. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment